Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL
Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and...
Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more
Remembering Arthur Rosenberg (1935 – 2018)
Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed...
Patient With HIV and Hodgkin Lymphoma Is Virus-Free Following Transplant
An allogeneic hematopoietic cell transplantation (alloHCT) intended to cure a patient’s refractory Hodgkin lymphoma (HL) may have also put his HIV virus into remission,...
Seventh Edition of ASH-SAP Coming Soon, CDC Responds to ASH’s Concerns About Opioid Guidelines
CDC Clarifies Opioid Prescribing Guideline at Urging of Hematology and Oncology GroupsHematologists, especially sickle cell disease (SCD) specialists, are welcoming a recent clarification from...
Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease
An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...
Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML
For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...
Can a Virtual Benign Hematology Consult Improve Access to and Quality of Care?
A multidisciplinary team of researchers developed a virtual benign hematology consultative service that can potentially reduce the time it takes a specialist to examine...
JULIET Analysis Finds Durable Responses With Tisagenlecleucel in DLBCL
Half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) responded to tisagenlecleucel, and approximately two-thirds of responders are expected to remain...
Carfilzomib Versus Bortezomib: Comparing Proteasome Inhibitors in Newly Diagnosed Myeloma
Carfilzomib plus melphalan and prednisone (KMP) failed to improve survival outcomes for patients with newly diagnosed multiple myeloma (MM) compared with bortezomib plus melphalan...
Ibrutinib and Obinutuzumab Combo Granted Approval for CLL/SLL
The U.S. Food and Drug Administration (FDA) approved the combination of ibrutinib and obinutuzumab for the treatment of patients with treatment-naïve chronic lymphocytic leukemia/small...
Current Issue
April 2019, Volume 5, Issue 5
This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.
